HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Pharmacia & Upjohn Rogaine Extra Strength marketing exclusivity award likely.

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

PHARMACIA & UPJOHN ROGAINE EXTRA STRENGTH EXCLUSIVITY AWARD LIKELY in light of new clinical trials the company conducted for its over-the-counter switch NDA (20-834) for the 5% minoxidil solution for hair regrowth. Marketing exclusivity for the stronger concentration Rogaine solution would provide Pharmacia & Upjohn an advantage the company did not receive for the switch of the original 2% OTC Rogaine. The extra strength version of the antibaldness treatment will be on shelves around Dec. 16, P&U said Nov. 17. Print ads supporting the launch of Rogaine 5% will break in January.

Table

View full table

Tags:
Latest Headlines

Need Advice About Advisory Committees, US FDA? Try Having Some

FDA Advisory Committee Reform: Does Listening Session Suggest No Major Near-Term Changes?

People On The Move: Appointments At Haleon, Bayer, Abdi Ibrahim

AI News: Lauder Expands Microsoft Partnership; Prose Beauty; Supply Chain Software; More

See All
UsernamePublicRestriction

Register

RS004877

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By